On January 17th, the "Innovating Together in the Ecological Landscape" evening gala was held at Xiaoshan Innovation Polis. Attendees included WANG Xinlai, Director of the Science and Technology Bureau of Xiaoshan District, CHEN Tao, President of Hangzhou Transfar Technology City Co., Ltd., GAO Yuan, Deputy Director of the Xiaoshan Innovation Polis Administration, CHEN Xingquan, Director of the Xiaoshan District Returned Overseas Students (University Students) Entrepreneurship Management Service Center, as well as leaders from various enterprises.
In the 2021 list of outstanding sci-tech innovation enterprises and service institutions, bioGenous was honored with the title of "2021 Outstanding Sci-Tech Innovation Enterprise" for its impressive achievements throughout the year.
*Professor ZHAO Bing delivered a speech
Professor ZHAO Bing, Chief Scientist of bioGenous and a professor at Fudan University, shared the milestones of bioGenous in 2021 as a representative of the company: The founding team of bioGenous has accumulated ten years of expertise in the organoid field. After the company’s establishment, it has rapidly developed and now has established over 20 normal tissue and tumor organoid culture systems. In August 2021, bioGenous launched its multi-cancer, whole-process tumor organoid kits. The company has collaborated with leading domestic companies in niche segments of innovative drugs, achieving several successful cases in organoid-based new drug development and non-clinical evaluation systems. The organoid kits and growth factors have comprehensively supported organoid research at universities and research institutes, and bioGenous successfully expanded into the overseas market with a presence in St. Louis. These achievements could not have been made without the strong support from all parties.
Looking ahead to 2022, the future is full of promise!
bioGenous is a leading one-stop provider of organoid technology products and solutions. The company has been deeply involved in basic organoid research and translational applications for many years. Since 2016, bioGenous has gradually established and perfected a full range of upstream organoid technologies, covering multiple tissue and tumor organoid culture, development and disease modeling, genetic manipulation, efficacy and toxicity evaluation, animal transplantation, multiomics atlas of organoids, organoid precision medicine, automated operations, and more. In 2020, to meet the explosive global demand for CDMO services in organoid technology, bioGenous built a 2,000-square-meter production facility that complies with international GMP standards for biopharmaceuticals. The company is committed to creating a standardized and modular CDMO service platform for basic biological and medical research, drug development, and precision medicine, leading a revolution in biomedical models and advancing human health.
